XP-8121 (levothyroxine sodium)

August 26, 2026: Xeris Biopharma Holdings (NASDAQ: XERS) announced a program overview webinar for XP-8121, a Phase 3-ready, once-weekly subcutaneous levothyroxine injection in development for hypothyroidism. The webinar is scheduled for September 9, 2026, at 10 a.m. ET and will cover unmet needs in hypothyroidism, market opportunity, and the company’s planned Phase 3 registrational program.

Xeris said the presentation will address Phase 3 trial design and objectives, primary and secondary endpoints, target patient population, expected development milestones, and anticipated regulatory timelines. The company stated XP-8121 is intended for patients who fail to achieve biochemical control with current oral therapy due to GI absorption issues.

The release does not report new clinical efficacy or safety data, but it indicates XP-8121 is advancing toward Phase 3 initiation, with further development and regulatory timing details expected at the September 9 webinar.